Joint Research Centre, EU.
National Food Institute, Technical University, Denmark.
Exp Biol Med (Maywood). 2022 Jan;247(1):1-75. doi: 10.1177/15353702211052280. Epub 2021 Nov 16.
There is an evolution and increasing need for the utilization of emerging cellular, molecular and technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.
新兴的细胞、分子和技术的应用以及用于食品、药品和个人护理产品安全性评估的新方法不断发展,且这种需求也在不断增长。这些新兴技术的融合也使得监管决策和审批的快速进展和方法成为可能。尽管新兴技术的发展可能允许监管决策的快速推进,但人们担心这些新技术尚未经过彻底评估,以确定它们是否已准备好单独或组合用于监管应用。这些综合技术进步的规模可能超过评估其适用性的能力,并且不允许常规应用这些新方法进行监管。有必要制定评估新技术的策略,以确定哪些技术已准备好用于监管用途。有机会应用这些潜在的更快、更准确和更具成本效益的方法仍然是一个重要目标,以促进将这些方法纳入监管用途。然而,如果没有明确的策略来快速、适当地评估新兴技术,那么这些努力的价值可能得不到认可,或者需要更长的时间。监管科学领域必须跟上这些技术先进领域的研究步伐,并了解这些新方法背后的科学原理。监管领域必须了解这些新颖方法的关键质量属性,并相互学习经验,以便培训工作人员,以应对新兴的全球监管挑战。此外,至关重要的是,监管界必须与技术开发者合作,利用集体能力制定评估这些新的和新颖的评估工具的策略。